Trials / Available
AvailableNCT05776160
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Kite, A Gilead Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Axicabtagene Ciloleucel | A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously. |
Timeline
- First posted
- 2023-03-20
- Last updated
- 2025-12-01
Locations
121 sites across 2 countries: United States, Japan
Source: ClinicalTrials.gov record NCT05776160. Inclusion in this directory is not an endorsement.